DBV Technologies Sees Unusually Large Options Volume (DBVT)

DBV Technologies SA – (NASDAQ:DBVT) was the recipient of unusually large options trading activity on Tuesday. Traders acquired 354 put options on the company. This represents an increase of approximately 608% compared to the typical daily volume of 50 put options.

Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new position in shares of DBV Technologies during the third quarter valued at $132,000. Quantbot Technologies LP bought a new position in shares of DBV Technologies during the third quarter valued at $146,000. Dynamic Technology Lab Private Ltd bought a new position in shares of DBV Technologies during the second quarter valued at $222,000. Commonwealth Equity Services Inc bought a new position in shares of DBV Technologies during the third quarter valued at $233,000. Finally, Belpointe Asset Management LLC bought a new position in shares of DBV Technologies during the third quarter valued at $343,000. 46.36% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on the stock. BidaskClub downgraded shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Societe Generale downgraded shares of DBV Technologies from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Zacks Investment Research downgraded shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of DBV Technologies in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. DBV Technologies presently has an average rating of “Hold” and a consensus price target of $49.63.

DBV Technologies (DBVT) opened at $26.23 on Thursday. DBV Technologies has a twelve month low of $20.08 and a twelve month high of $50.57.

TRADEMARK VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://weekherald.com/2018/02/15/dbv-technologies-sees-unusually-large-options-volume-dbvt.html.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply